Viro-immunological dynamics in HIV-1-infected subjects receiving once-a-week emtricitabine to delay treatment change after failure: A pilot randomised trial

Journal of Clinical Virology

Volumn 47, Issue 3, 2010, Pages 253-257

  Soria, Alessandro ^a   Danise, Anna ^a   Galli, Laura ^a   Tiberi, Simon ^a   Seminari, Elena ^a   Cossarini, Francesca ^a   Bigoloni, Alba ^a   Marcotullio, Simone ^b   Lazzarin, Adriano ^a,c   Castagna, Antonella ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b Nadir Onlus Foundation   (Italy)

^c VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Emtricitabine; Lamivudine; M184V mutation; Randomised clinical trial; Salvage regimen; Virological failure

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; EMTRICITABINE; LAMIVUDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG TREATMENT FAILURE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INTRAVENOUS DRUG ABUSE; MALE; MALE HOMOSEXUAL; MONOTHERAPY; NONHUMAN; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THERAPY DELAY; TREATMENT OUTCOME; VIRUS IMMUNITY;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DEOXYCYTIDINE; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MUTATION, MISSENSE; SALVAGE THERAPY; TREATMENT FAILURE; VIRAL LOAD;

EID: 76449116499     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2009.12.007     Document Type: Article

References (15)

1. Lima V., Hudson E., Wynhoven B., Yip B., Hogg R., Montaner J., et al. Drastically declining incidence of HIV drug resistance: the end of the beginning? [abstract 895]. 15th Conference on Retroviruses and Opportunistic Infections. 3-6 February, Boston, USA (2008)
2. Castagna A., Danise A., Menzo S., Galli L., Gianotti N., Carini E., et al. Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184 V study). AIDS 20 (2006) 795-803
3. Campbell T.B., Shulman N.S., Johnson S.C., Zolopa A.R., Young R.K., Bushman L., et al. Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection. Clin Infect Dis 41 (2005) 236-242
4. Gianotti N., Tiberi S., Menzo S., Danise A., Boeri E., Galli L., et al. HIV-1 replication capacity and genotype changes in patients undergoing treatment interruption or lamivudine monotherapy. J Med Virol 80 (2008) 201-208
5. Goicoechea M., and Haubrich R. CD4 lymphocyte percentage versus absolute CD4 lymphocyte count in predicting HIV disease progression: an old debate revisited. J Infect Dis 192 (2005) 945-947
6. Burcham J., Marmor R., Dubin M., Tindall B., Cooper D.A., Berry G., et al. CD4% is the best predictor of development of AIDS in a cohort of HIV-infected homosexual men. AIDS 5 (1991) 365-372
7. 3. J Infect Dis 192 (2005) 950-957
8. Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr W.M., Lundgren J.D., Neaton J.D., Gordin F., Abrams D., et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 355 (2006) 2283-2296
9. Hammer S.M., Eron Jr. J.J., Reiss P., Schooley R.T., Thompson M.A., Walmsley S., et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 300 (2008) 555-570
10. Maggiolo F., Airoldi M., Callegaro A., Martinelli C., Dolara A., Bini T., et al. CD4 cell-guided scheduled treatment interruptions in HIV-infected patients with sustained immunologic response to HAART. AIDS 27 (2009) 799-807
11. Hirschel B., and Flanigan T. Is it smart to continue to study treatment interruptions?. AIDS 27 (2009) 757-759
12. d'Arminio Monforte A., Cozzi-Lepri A., Phillips A., De Luca A., Murri R., Mussini C., et al. Interruption of highly active antiretroviral therapy in HIV clinical practice: results from the Italian Cohort of Antiretroviral-Naive Patients. J Acquir Immune Defic Syndr 38 (2005) 407-416
13. Antiretroviral Therapy Cohort Collaboration (ART-CC), Mugavero M.J., May M., Harris R., Saag M.S., Costagliola D., et al. Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice?. AIDS 30 (2008) 2481-2492
14. Bestetti A., Soria A., Galli L., Danise A., Sala S., Bossolasco S., et al. Dynamics of the M184V mutation by allele-specific PCR (AS-PCR) in patients receiving lamivudine or emtricitabine monotherapy or undergoing treatment interruption (TI) [abstract No. 112]. 17th International HIV Drug Resistance Workshop. 10-14 June, Sitges, Spain (2008)
15. Paredes R., Sagar M., Marconi V.C., Hoh R., Martin J.N., Parkin N.T., et al. In vivo fitness cost of the M184V mutation in multidrug-resistant human immunodeficiency virus type 1 in the absence of lamivudine. J Virol 83 (2009) 2038-2043